This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Hajjeh, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Hajjeh, R. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3242-3244, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole

M. A. Pfaller,1,* S. A. Messer,1 R. J. Hollis,1 R. N. Jones,1 G. V. Doern,1 M. E. Brandt,2 and R. A. Hajjeh2

Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa,1 and Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia2

Received 16 July 1998/Returned for modification 21 August 1998/Accepted 15 September 1998

BMS-207147, Sch 56592, and voriconazole are three new investigational triazoles with broad-spectrum antifungal activity. The in vitro activities of these three agents were compared with those of itraconazole and fluconazole against 1,300 bloodstream isolates of Candida species obtained from over 50 different medical centers in the United States. The MICs of all of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards method using RPMI 1640 as a test medium. BMS-207147, Sch 56592, and voriconazole were all quite active against all Candida sp. isolates (MICs for 90% of the isolates tested [MIC90s], 0.5, 1.0, and 0.5 µg/ml, respectively). Candida albicans was the most susceptible species (MIC90s, 0.03, 0.06, and 0.06 µg/ml, respectively), and C. glabrata was the least susceptible (MIC90s, 4.0, 4.0, and 2.0 µg/ml, respectively). BMS-207147, Sch 56592, and voriconazole were all more active than itraconazole and fluconazole against C. albicans, C. parapsilosis, C. tropicalis, and C. krusei. There existed a clear rank order of in vitro activity of the five azoles examined in this study when they were tested versus C. glabrata: voriconazole > BMS-207147 = Sch 56592 = itraconazole > fluconazole (MIC90s, 2.0, 4.0, 4.0, 4.0, and 64 µg/ml, respectively). For isolates of Candida spp. with decreased susceptibility to both itraconazole and fluconazole, the MICs of BMS-207147, Sch 56592, and voriconazole were also elevated. These results suggest that BMS-207147, Sch 56592, and voriconazole all possess promising antifungal activity and that further in vitro and in vivo investigations are warranted to establish the clinical value of this improved potency.

* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 394-9566. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu.

Antimicrobial Agents and Chemotherapy, December 1998, p. 3242-3244, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Karlsson, M. O., Lutsar, I., Milligan, P. A. (2009). Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies. Antimicrob. Agents Chemother. 53: 935-944 [Abstract] [Full Text]  
  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Trofa, D., Gacser, A., Nosanchuk, J. D. (2008). Candida parapsilosis, an Emerging Fungal Pathogen. Clin. Microbiol. Rev. 21: 606-625 [Abstract] [Full Text]  
  • Lortholary, O., Dannaoui, E., Raoux, D., Hoinard, D., Datry, A., Paugam, A., Poirot, J.-L., Lacroix, C., Dromer, F., the YEASTS Group, (2007). In Vitro Susceptibility to Posaconazole of 1,903 Yeast Isolates Recovered in France from 2003 to 2006 and Tested by the Method of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 51: 3378-3380 [Abstract] [Full Text]  
  • Seifert, H., Aurbach, U., Stefanik, D., Cornely, O. (2007). In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates. Antimicrob. Agents Chemother. 51: 1818-1821 [Abstract] [Full Text]  
  • Liu, P., Foster, G., LaBadie, R., Somoza, E., Sharma, A. (2007). Pharmacokinetic Interaction between Voriconazole and Methadone at Steady State in Patients on Methadone Therapy. Antimicrob. Agents Chemother. 51: 110-118 [Abstract] [Full Text]  
  • Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M. (2006). In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts.. Antimicrob. Agents Chemother. 50: 2009-2015 [Abstract] [Full Text]  
  • Messer, S. A., Jones, R. N., Fritsche, T. R. (2006). International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003).. J. Clin. Microbiol. 44: 1782-1787 [Abstract] [Full Text]  
  • Yan, J.-H., Marino, M. R., Smith, R. A., Kanamaluru, V., O'Mara, E. M., Grasela, D. M. (2006). The Effect of Ravuconazole on the Pharmacokinetics of Nelfinavir in Healthy Male Volunteers. J Clin Pharmacol 46: 193-200 [Abstract] [Full Text]  
  • Carrillo-Munoz, A.-J., Quindos, G., Ruesga, M., Alonso, R., del Valle, O., Hernandez-Molina, J. M., McNicholas, P., Loebenberg, D., Santos, P. (2005). Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 55: 317-319 [Abstract] [Full Text]  
  • Gao, H., Pennesi, M. E., Shah, K., Qiao, X., Hariprasad, S. M., Mieler, W. F., Wu, S. M., Holz, E. R. (2004). Intravitreal Voriconazole: An Electroretinographic and Histopathologic Study. Arch Ophthalmol 122: 1687-1692 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Lyman, C. A., Groll, A. H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N. A., Walsh, T. J. (2004). Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 48: 1188-1196 [Abstract] [Full Text]  
  • Pearson, M. M, Rogers, P D., Cleary, J. D, Chapman, S. W (2003). Voriconazole: A New Triazole Antifungal Agent. The Annals of Pharmacotherapy 37: 420-432 [Abstract] [Full Text]  
  • Chryssanthou, E., Cuenca-Estrella, M. (2002). Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing Proposed Standard and the E-Test with the NCCLS Broth Microdilution Method for Voriconazole and Caspofungin Susceptibility Testing of Yeast Species. J. Clin. Microbiol. 40: 3841-3844 [Abstract] [Full Text]  
  • Venkataramanan, R., Zang, S., Gayowski, T., Singh, N. (2002). Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes. Antimicrob. Agents Chemother. 46: 3091-3093 [Abstract] [Full Text]  
  • Laverdiere, M., Hoban, D., Restieri, C., Habel, F. (2002). In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50: 119-123 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Diekema, D. J. (2002). In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp.. Antimicrob. Agents Chemother. 46: 1723-1727 [Abstract] [Full Text]  
  • PELLETIER, R., LORANGER, L., MARCOTTE, H., DE CAROLIS, E. (2002). Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol 51: 479-483 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J. (2002). Clinical Evaluation of a Frozen Commercially Prepared Microdilution Panel for Antifungal Susceptibility Testing of Seven Antifungal Agents, Including the New Triazoles Posaconazole, Ravuconazole, and Voriconazole. J. Clin. Microbiol. 40: 1694-1697 [Abstract] [Full Text]  
  • Clemons, K. V., Martinez, M., Calderon, L., Stevens, D. A. (2002). Efficacy of Ravuconazole in Treatment of Systemic Murine Histoplasmosis. Antimicrob. Agents Chemother. 46: 922-924 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., Hollis, R. J. (2002). Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40: 852-856 [Abstract] [Full Text]  
  • Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., Donowitz, L. G. (2001). Fluconazole Prophylaxis against Fungal Colonization and Infection in Preterm Infants. NEJM 345: 1660-1666 [Abstract] [Full Text]  
  • Clemons, K. V., Stevens, D. A. (2001). Efficacy of Ravuconazole in Treatment of Mucosal Candidosis in SCID Mice. Antimicrob. Agents Chemother. 45: 3433-3436 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Mills, K., Bolmstrom, A., Jones, R. N. (2001). Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of Candida Species. J. Clin. Microbiol. 39: 4387-4389 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Mills, K., Bolmstrom, A., Jones, R. N. (2001). Evaluation of Etest Method for Determining Posaconazole MICs for 314 Clinical Isolates of Candida Species. J. Clin. Microbiol. 39: 3952-3954 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N. (2001). In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans. Antimicrob. Agents Chemother. 45: 2862-2864 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., The SENTRY Participant Group, (2001). International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 39: 3254-3259 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., Walsh, T. J. (2001). Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia. Antimicrob. Agents Chemother. 45: 857-869 [Abstract] [Full Text]  
  • Roberts, J., Schock, K., Marino, S., Andriole, V. T. (2000). Efficacies of Two New Antifungal Agents, the Triazole Ravuconazole and the Echinocandin LY-303366, in an Experimental Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 44: 3381-3388 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Houston, A., Mills, K., Bolmstrom, A., Jones, R. N. (2000). Evaluation of the Etest Method for Determining Voriconazole Susceptibilities of 312 Clinical Isolates of Candida Species by Using Three Different Agar Media. J. Clin. Microbiol. 38: 3715-3717 [Abstract] [Full Text]  
  • Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel, F. Jr., Moss, E. L. Jr., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C., Arnold, B., Antonacci, B., Parmegiani, R., Yarosh-Tomaine, T., Miller, G. H., Hare, R. S. (2000). In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44: 2017-2022 [Abstract] [Full Text]  
  • Li, R.-K., Ciblak, M. A., Nordoff, N., Pasarell, L., Warnock, D. W., McGinnis, M. R. (2000). In Vitro Activities of Voriconazole, Itraconazole, and Amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. 44: 1734-1736 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Moore, C. B., Walls, C. M., Denning, D. W. (2000). In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin B. Antimicrob. Agents Chemother. 44: 441-443 [Abstract] [Full Text]  
  • Diekema, D. J., Pfaller, M. A., Messer, S. A., Houston, A., Hollis, R. J., Doern, G. V., Jones, R. N., The SENTRY PARTICIPANTS GROUP, (1999). In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob. Agents Chemother. 43: 2236-2239 [Abstract] [Full Text]  
  • Lozano-Chiu, M., Arikan, S., Paetznick, V. L., Anaissie, E. J., Rex, J. H. (1999). Optimizing Voriconazole Susceptibility Testing of Candida: Effects of Incubation Time, Endpoint Rule, Species of Candida, and Level of Fluconazole Susceptibility. J. Clin. Microbiol. 37: 2755-2759 [Abstract] [Full Text]  
  • Hoban, D. J., Zhanel, G. G., Karlowsky, J. A. (1999). In Vitro Susceptibilities of Candida and Cryptococcus neoformans Isolates from Blood Cultures of Neutropenic Patients. Antimicrob. Agents Chemother. 43: 1463-1464 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Gee, S., Joly, S., Pujol, C., Sullivan, D. J., Coleman, D. C., Soll, D. R. (1999). In Vitro Susceptibilities of Candida dubliniensis Isolates Tested against the New Triazole and Echinocandin Antifungal Agents. J. Clin. Microbiol. 37: 870-872 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»